Nyse Ebs News Today

Emergent BioSolutions (NYSE:EBS – Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of ($3.65) by $4.24, Zacks reports. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 17.91%. The firm had […]

Nearly 9 in 10 Americans surveyed agree opioid overdoses are a concern for teenagers and college students; parents in the survey want life-saving treatment...

Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 3,153 put options on the stock. This is an increase of 344% compared to the typical daily volume of 710 put options. Emergent BioSolutions Stock Performance Shares of NYSE:EBS traded up $0.03 on Wednesday, […]

First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of...

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and...

Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) was the target of a significant drop in short interest in March. As of March 15th, there was short interest totalling 4,910,000 shares, a drop of 20.8% from the February 29th total of 6,200,000 shares. Based on an average trading volume of 3,000,000 shares, the short-interest ratio […]

Benchmark upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, MarketBeat reports. They currently have $5.00 price objective on the biopharmaceutical company’s stock. A number of other analysts have also issued reports on the stock. JPMorgan Chase […]

Emergent BioSolutions (NYSE:EBS – Get Free Report) is scheduled to post its quarterly earnings results on Monday, February 26th. Emergent BioSolutions (NYSE:EBS – Get Free Report) last posted its quarterly earnings data on Monday, December 11th. The biopharmaceutical company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by […]

Emergent BioSolutions (NYSE:EBS – Get Free Report) and Avid Bioservices (NASDAQ:CDMO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, analyst recommendations, earnings, valuation, dividends and institutional ownership. Analyst Recommendations This is a summary of […]

Third Quarter 2023 Total Revenues of $271M, above the prior guidance rangeThird Quarter 2023 Pre-Tax Loss of  $(266)M and Adjusted EBITDA(2) of $20MUpdates...